Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Trial details
- Registry ID
- NCT06777433
- Drugs studied
- RAD101 (18F-FPIA)
TrialRedline tracks 2 clinical trials sponsored by Radiopharm Theranostics, Ltd: 1 Phase 2, 1 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433 | RAD101 (18F-FPIA) | Active not recruiting | 2026-04-23Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 | 177Lu-BetaBart, BetaBart + unlabeled BetaBart | Recruiting | 2027-12Estimated |
Names as written in the registry records.
NCT06777433 · Radiopharm Theranostics, Ltd
Before: Estimated. After: Actual.
Before: Jan 2026. After: 23 Apr 2026.
Before: Recruiting. After: Active not recruiting.